Bimosiamose (TBC 1269) (Synonyms: TBC 1269) |
| Catalog No.GC33908 |
Bimosiamose (TBC 1269) (TBC-1269) is a nonoligosaccharide pan-selectin antagonist with IC50s of 88 μM, 20 μM, and 86 μM for E-selectin, P-selectin, and L-selectin, respectively.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 187269-40-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Bimosiamose is a pan-selectin antagonist, inhibits E-, P-, and L-selectin with IC50s of 88 μM, 20 μM, and 86 μM, respectively, and can be used in the research of inflammatory disease.
Bimosiamose is a pan-selectin antagonist, inhibits E-, P-, and L-selectin with IC50s of 88 μM, 20 μM, and 86 μM, respectively, and can be used in the research of inflammatory disease[1].
Bimosiamose (25 mg/kg, i.v.) significantly improves the survival in rats subjected to severe hepatic ischemia and reperfusion. Bimosiamose also causes lower ALT enzyme levels and decreases neutrophil infiltration[1].
[1]. Palma-Vargas JM, et al. Small-molecule selectin inhibitor protects against liver inflammatory response after ischemia and reperfusion. J Am Coll Surg. 1997 Oct;185(4):365-72.
Average Rating: 5 (Based on Reviews and 10 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *